Table of contents
- Introduction
- Estimation of total cardiovascular risk and implications for dyslipidaemia management
- New low-density lipoprotein cholesterol-lowering therapies
- Combination of lipid-lowering therapies during index hospitalization for acute coronary syndromes
- Lipoprotein(a)
- Hypertriglyceridaemia
- Primary prevention in people with human immunodeficiency virus infection
- Patients with cancer at high or very high chemotherapy-related cardiovascular toxicity risk
- Dietary supplements
Our mission: To reduce the burden of cardiovascular disease.